Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Does testosterone administration affect the prostate?

Does testosterone administration affect the prostate? Millions of men are candidates for testosterone replacement therapy (TRT), but a major safety concern, the effects of TRT on the prostate, has been poorly understood until recently. In the past few years, a meta-analysis showed that endogenous hormone levels have little relationship to prostate cancer. Another review showed that during TRT, cancer develops with no more frequency than in the overall population. A randomized trial focusing on TRT’s tissue effects showed that no treatment-related change was noted in prostate tissue composition, hormone levels, biomarkers, gene expression, or cancer incidence. And in animal models, testosterone alone is at most only a weak prostatic carcinogen. Thus, recent years have seen clarification of the prostate safety issue. Future areas of interest include using TRT in men believed to be cured of prostate cancer and, importantly, developing cancer-specific biomarkers (eg, PCA3 gene) to help diagnose and monitor men receiving TRT. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Sexual Health Reports Springer Journals

Does testosterone administration affect the prostate?

Current Sexual Health Reports , Volume 5 (4) – Nov 25, 2008

Loading next page...
 
/lp/springer-journals/does-testosterone-administration-affect-the-prostate-Kp0wcue7kc

References (50)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Urology; Endocrinology
ISSN
1548-3584
eISSN
1548-3592
DOI
10.1007/s11930-008-0034-5
Publisher site
See Article on Publisher Site

Abstract

Millions of men are candidates for testosterone replacement therapy (TRT), but a major safety concern, the effects of TRT on the prostate, has been poorly understood until recently. In the past few years, a meta-analysis showed that endogenous hormone levels have little relationship to prostate cancer. Another review showed that during TRT, cancer develops with no more frequency than in the overall population. A randomized trial focusing on TRT’s tissue effects showed that no treatment-related change was noted in prostate tissue composition, hormone levels, biomarkers, gene expression, or cancer incidence. And in animal models, testosterone alone is at most only a weak prostatic carcinogen. Thus, recent years have seen clarification of the prostate safety issue. Future areas of interest include using TRT in men believed to be cured of prostate cancer and, importantly, developing cancer-specific biomarkers (eg, PCA3 gene) to help diagnose and monitor men receiving TRT.

Journal

Current Sexual Health ReportsSpringer Journals

Published: Nov 25, 2008

There are no references for this article.